Vitamin B3 prevents glaucoma in laboratory mice

February 16, 2017, Jackson Laboratory
Credit: Martha Sexton/public domain

In mice genetically predisposed to glaucoma, vitamin B3 added to drinking water is effective at preventing the disease, a research team led by Jackson Laboratory Professor and Howard Hughes Medical Investigator Simon W.M. John reports in the journal Science.

The vitamin administration was surprisingly effective, eliminating the vast majority of age-related molecular changes and providing a remarkably robust protection against . It offers promise for developing inexpensive and safe treatments for glaucoma patients.

Glaucoma is one of the most common neurodegenerative diseases, affecting an estimated 80 million people worldwide. In most glaucoma patients, harmfully high pressure inside the eye or intraocular pressure leads to the progressive dysfunction and loss of . Retinal ganglion cells are the neuronal cells that connect the eye to the brain via the optic nerve. Increasing age is a key risk factor for glaucoma, contributing to both harmful elevation of intraocular pressure and increased neuronal vulnerability to pressure-induced damage.

"We wanted to identify key age-related susceptibility factors that change with age in the eye," John says, "and that therefore increase vulnerability to disease and in particular neuronal disease." By understanding general age-related mechanism, there is the potential to develop new interventions to generally protect from common age-related disease processes in many people. Conducting a variety of genomic, metabolic, neurobiological and other tests in mice susceptible to inherited glaucoma, compared to control mice, the researchers discovered that NAD, a molecule vital to energy metabolism in neurons and other cells, declines with age.

"There's an analogy with an old motorbike," John says. "It runs just fine, but little things get less reliable with age. One day you stress it: you drive it up a steep hill or you go on really long journey and you get in trouble. It's less reliable than a new bike and it's going to fail with a higher frequency than that new bike."

The decrease in NAD levels reduces the reliability of neurons' , especially under stress such as increased intraocular pressure. "Like taking that big hill on your old bike, some things are going to fail more often," John says. "The amount of failure will increase over time, resulting in more damage and disease progression."

In essence, the treatments of vitamin B3 (nicotinamide, an amide form of vitamin B3, also called niacinamide) boosted the metabolic reliability of aging retinal ganglion cells, keeping them healthier for longer. "Because these cells are still healthy, and still metabolically robust," says JAX Postdoctoral Associate Pete Williams, first author of the study, "even when high turns on, they better resist damaging processes."

The researchers also found that a single gene-therapy application of Nmnat1 (the gene for an enzyme that makes NAD from nicotinamide) prevented glaucoma from developing in this mouse model. "It can be a problem for patients, especially the elderly, to take their drugs every day and in the correct dose," Williams says. "So gene therapy could be a one-shot, protective treatment." He notes that gene therapies, through injections into the eye, have been approved for a handful of very rare, human genetic eye disorders, and their demonstration of an important age-dependent factor may enable gene therapy for more common eye disease.

John says that the team is pursuing clinical partnerships to begin the process of testing the effectiveness of vitamin B3 treatment in glaucoma patients. They are also exploring potential applications for the treatment in other diseases involving neurodegeneration.

Explore further: Research advance may lead to new treatments for glaucoma

More information: "Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice," Science, science.sciencemag.org/cgi/doi … 1126/science.aal0092

Related Stories

Research advance may lead to new treatments for glaucoma

March 22, 2016
Researchers have developed a tool to not only model the underlying disease mechanisms of glaucoma, but also to help discover and test new pharmacological strategies to combat the neurodegeneration that occurs in patients ...

New device could save glaucoma patients' eyesight

December 6, 2016
People with high-risk glaucoma will be able to monitor their disease, anywhere, anytime, thanks to a new device developed by an FIU professor.

Targeted X-ray treatment of mice prevents glaucoma

March 19, 2012
Jackson Laboratory researchers have demonstrated that a single, targeted x-ray treatment of an individual eye in young, glaucoma-prone mice provided that eye with apparently life-long and typically complete protection from ...

Identified genetic interaction offers possible new target for glaucoma therapy

September 10, 2015
Scientists at the University of California, San Diego School of Medicine have elucidated a genetic interaction that may prove key to the development and progression of glaucoma, a blinding neurodegenerative disease that affects ...

Early retina cell changes in glaucoma identified

February 11, 2015
Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular ...

Experimental drug, implanted in eye, could fight glaucoma

October 14, 2016
An experimental drug, consisting of cells manufactured and implanted in the eye to stimulate optic nerve growth and activity, could be an entirely new way of fighting glaucoma, according to BrightFocus Foundation.

Recommended for you

In effort to treat rare blinding disease, researchers turn stem cells into blood vessels

February 13, 2018
People who inherit a mutated version of the ATF6 gene are born with a malformed or missing fovea, the eye region responsible for sharp, detailed vision. From birth, their vision is severely limited, and there is no cure. ...

Antioxidant therapy prevents devastating vision loss when added to standard-of-care on rare birth defect

February 5, 2018
A new study led by vision researchers at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and VA Western New York Healthcare System has demonstrated that the addition of widely available ...

Genetic basis for glaucoma uncovered

January 30, 2018
In two recent publications, Northwestern Medicine scientists and international collaborators discovered mutations that cause improper drainage and a buildup of ocular pressure leading to one form of congenital glaucoma, and ...

Study advances gene therapy for glaucoma

January 16, 2018
While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains ...

New study offers added hope for patients awaiting corneal transplants

January 9, 2018
New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to correct eye problems ...

Diabetic blindness caused and reversed "trapped" immune cells in rodent retinas

January 3, 2018
Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.